Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Launched by UNIVERSITY OF MICHIGAN · Dec 6, 2022

Keywords

ClinConnect Summary

This clinical trial, called RESOLVE, is studying how focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) can come back after a kidney transplant. These conditions can lead to problems like swelling, loss of kidney function, and a lower quality of life. The goal of the study is to collect information and samples from people who have had or will have a kidney transplant due to FSGS or MCD. This will help researchers better understand these diseases and develop more effective treatments.

To participate in the trial, you need to have been diagnosed with FSGS or MCD before your transplant and have had your transplant since 2000. Unfortunately, if your condition is due to another illness, you wouldn't be eligible. If you join the study, you can expect to share your health information and possibly contribute samples that can aid in important research. This effort will help build a community of knowledge about these diseases, ultimately leading to better care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Retrospective non-consented participant group had a transplant from the year 2000 and onward.
• • Diagnosis of FSGS or MCD in the native kidney (prior to transplant).
• Exclusion Criteria:
• • Pathologic diagnosis other than FSGS or MCD
• • FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)

Trial Officials